Clinical Trial Update: Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate [Phase 2]

View source ↗

Summary

This entry reports results from a Phase 2 trial evaluating sorafenib in patients with malignant gastrointestinal stromal tumor that progressed after imatinib an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• Nexavar (Sorafenib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Gastrointestinal Stromal Tumor | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2014-01-21